Mediaboss Marketing

PRESS RELEASE: CENTROTEC Sustainable AG: CENTROTEC meets earnings forecast for 2013 - forecast for 2014: slight growth in revenue and earnings

DGAP-News: CENTROTEC Sustainable AG / Key word(s): Preliminary Results/Forecast CENTROTEC Sustainable AG: CENTROTEC meets earnings forecast for 2013 - forecast for 2014: slight growth in revenue and earnings

03.02.2014 / 07:30

=--------------------------------------------------------------------

Brilon, February 3, 2014: CENTROTEC Sustainable AG, Brilon, generated revenue of EUR 525 million in the 2013 financial year (unaudited; previous year EUR 533.8 million). Based on provisional calculations, the prior-year operating result (EBIT) of EUR 35.2 million will be just exceeded, in line with the earnings forecast made one year ago. CENTROTEC starts the 2014 financial year on a cautiously optimistic note. The signs of general economic stabilisation in many European markets that have latterly performed very weakly is one important factor, along with the fundamentally positive development of the home market Germany. On that basis, CENTROTEC anticipates slightly higher revenue and earnings for the current financial year. It will only be possible to give a more precise forecast as the year progresses because the performance of international markets in particular, but also the impact of the regulatory changes taking place in Germany, are currently still very difficult to anticipate. The audited 2013 financial statements and Annual Report will be published at the Annual Press Conference on March 27, 2013. The group's new Chief Financial Officer, Dr. Thomas Kneip, will also be introduced at that event. Dr. Kneip was appointed with effect from January 1, 2014 and will be based at the group's biggest location, the headquarters of Wolf in Mainburg, Bavaria. His predecessor Anton Hans will continue to perform the task of Chief Risk and Audit Officer from Brilon.

CENTROTEC Sustainable AG CENTROTEC Sustainable AG enjoys a presence in over 50 different countries through subsidiaries and sales partners. The principal group companies are Wolf, Brink Climate Systems and Ned Air in the Climate Systems segment, specialising in heating, climate control and ventilation technology e.g. in the form of solar thermal systems, CHP units and home ventilation systems with heat recovery, as well as Ubbink and Centrotherm in the Gas Flue Systems segment, with their focus on gas flue and air ducting systems. CENTROTEC is consequently Europe's only listed full-service provider of heating and climate control technology, solar thermal systems and energy-saving solutions for buildings.

CENTROTEC Sustainable AG, Am Patbergschen Dorn 9, D-59929 Brilon, Germany ISIN: DE0005407506, WKN: 540750, home stock exchange: Frankfurt am Main; indices: SDAX, Prime All Share, Prime Industrial For further information, contact: CENTROTEC Sustainable AG, Carsten Vogt, Tel.: +49 (0)2961 96631-103 or MetaCom GmbH, Georg Biekehr, Tel: +49 (0)6181 98280-30

End of Corporate News

=--------------------------------------------------------------------

03.02.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement.

View post:
PRESS RELEASE: CENTROTEC Sustainable AG: CENTROTEC meets earnings forecast for 2013 - forecast for 2014: slight growth ...

PRESS RELEASE: MOLOGEN AG: Final results from renal cancer trial with MGN1601 presented at ASCO Genitourinary Cancers Symposium

DGAP-News: MOLOGEN AG / Key word(s): Study MOLOGEN AG: Final results from renal cancer trial with MGN1601 presented at ASCO Genitourinary Cancers Symposium

03.02.2014 / 09:07

=--------------------------------------------------------------------

MOLOGEN AG: Final results from renal cancer trial with MGN1601 presented at ASCO Genitourinary Cancers Symposium

- Treatment with MGN1601 safe and well tolerated

- Promising median overall survival data in a subgroup of patients

- Presentation at ASCO - GU attracted great interest

Berlin, February 3, 2014 - Final results from the phase I/II clinical study with MGN1601 (ASET trial) have been presented in a poster at the 2014 Genitourinary Cancers Symposium. The trial evaluated safety and tolerability of MGN1601 in 19 heavily pretreated patients with advanced renal cancer which had no other treatment options. The monotherapy with tumor cell-based cancer vaccine MGN1601 was well tolerated and safe. Furthermore, treatment with MGN1601 resulted in promising median overall survival data in a subgroup of patients. One patient achieved a long term partial response and another patient up to 60 weeks with disease control. Putative predictive biomarkers were identified from pre-treatment characteristics, which were associated with longer overall survival. Those may allow identifying patients more likely to benefit from this innovative vaccination approach with MGN1601.

In total 19 patients were included into the study and received at least one MGN1601 injection (ITT population). 10 patients completed the study per protocol (PP population). 9 patients discontinued the study early without completing the planned treatment phase due to the worsening of their tumor disease (non-PP population).

Original post:
PRESS RELEASE: MOLOGEN AG: Final results from -2-

03.02.14 07:00 Dow Jones Newswires

PRESS RELEASE: AURELIUS successfully closes sale of brightONE's Healthcare operations to T-Systems

DGAP-News: AURELIUS AG / Key word(s): Acquisition AURELIUS successfully closes sale of brightONE's Healthcare operations to T-Systems

03.02.2014 / 07:00

=--------------------------------------------------------------------

AURELIUS successfully closes sale of brightONE's Healthcare operations to T-Systems

- Successful closing of the transaction on January 31, 2014

- Additional transactions planned in coming months

Munich, February 3, 2014 - The Munich-based AURELIUS Group (ISIN DE000A0JK2A8) successfully closed the sale of the Healthcare operations of its subsidiary brightONE to T-Systems International GmbH ('T-Systems'). After the transaction was agreed between AURELIUS and T-Systems on December 20, 2013, it has now also been approved by the responsible antitrust authorities. For T-Systems, Deutsche Telekom AG's IT subsidiary, this acquisition is another important step on the way to becoming an integrated provider of IT healthcare. T-Systems received access to these strategically markets as a result of its takeover of brightONE Healthcare's German and Dutch units. In addition, T-Systems is also taking over brightONE Healthcare's Service and Maintenance business, which is run from India.

AURELIUS took over brightONE in July 2013 from the Finnish-based Tieto Group and has since supported the group in its reorientation as a provider of innovative IT and engineering solutions. brightONE had last taken over Telenet GmbH Kommunikationsysteme, thereby further expanding its activities in the areas of Customer Experience Management and Testing Solutions.

More:
PRESS RELEASE: AURELIUS successfully closes sale of brightONE's Healthcare operations to T-Systems

geniusitzone.com -Popular Bangla Technology Blog
You can Visit My site For More Information http://geniusitzone.com geniusitzone is the complete unicode based bangla technology blogging platform in Banglade...

By: nazmul hasan

Link:
geniusitzone.com -Popular Bangla Technology Blog - Video

Anticipated is a word that gets bandied about far too much in the music press: a word that is the default choice for any band returning to action after a year or more out of the limelight. But while some may not totally be deserving of the word, with Metronomyits hard to argue that it doesnt fit.

Three years after their critically praised third album The English Riviera, they are on the verge of once again staking a claim for becoming everybodys new favourite band with a fresh collection of lo-fi but heartfelt pop album four, Love Letters, is out in March.

The bands first show since an appearance at a German festival in September 2012 is an intimate affair in front of an audience consisting of friends, family and fans. Those in attendance witness a series of sometimes kitsch, 80s-inspired pop featuring a sprinkling of its makers early spirit.

The bands first incarnation saw members sport black t-shirts with flashing white lights attached, pulling off synchronised dance moves soundtracked by three-minute bursts of drum-machine outsider pop. But with each passing album the Joseph Mount-fronted outfit has taken several steps forward, and is now a finely tuned pop machine.

Tonights show is another sign that Metronomy is not a band willing to remain still. Its an educational 80-minute lesson in where the band is at right now.

Mount humbly apologises for the band being out of practice and also the amount of new material, stressing that this return to playing live after 16 months is an opportunity to try out new things. But while the set is heavily tailored towards road-testing the material from Love Letters, the show isnt all about airing previously unheard songs.

Songs such as Radio Ladio and the dark, twisted basslines of Holiday and She Wants gently snuggle up against material that makes up the bands forthcoming LP, without ever sounding out of place. Receiving live debuts are a host of tracks, including Boy Racers, Call Me, The Most Immaculate Haircut and recent single Im Aquarius.

Metronomy appreciate what effect their past has had on their present, so the older numbers are welcomed. The contrast between The English Riviera material and that of Love Letters is indicative, too, of the progression this band could take in its future.

A pop band designed to please: this is what Metronomy have become, through a sequence of neatly refined long-play releases. And long may that status continue.

- - -

Excerpt from:
Metronomy - Live At The Old Market, Brighton